Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease.

Alzheimers Dement (N Y) · 2016 · PMC5644268 · PMID 29067300

Europe PMC DOI

hedged sentence

0.0810

closest p · 1.6× alpha

0.0810

boldest claim

The sentences

did not reach statistical significanceP = .081so close (0.05 < p ≤ 0.1)

Although there were numerically more subjects who discontinued from the low-dose (200 mg/kg) IGIV and low-dose (2 mL) placebo treatment groups (24.7%) compared with the high-dose (400 mg/kg) IGIV and placebo (4 mL) groups (17.3%), this trend did not reach statistical significance ( P = .081).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.